Mission

At ProNeurogen, our mission is to change the trajectory of vascular dementia by developing innovative therapies that slow disease progression, preserve cognitive function, and help people maintain brain health for life.

Vision

To lead the world in protecting brain health-bringing life-changing treatments to millions at risk of cognitive decline from neurodegenerative disease.

ProNeurogen was founded in 2013 as a spin-out from the University of Arizona by Dr. Meredith Hay to translate Mas receptor biology into therapeutic development. The company is a privately held Delaware C-corporation headquartered in Tucson, Arizona, operating through a virtual model supported by research and manufacturing partners. It has been financed primarily through competitive, non-dilutive federal grants from the National Institutes of Health and the U.S. Department of Defense. Scientific guidance is provided by a scientific board including leaders from the University of Arizona, Weill Cornell Medicine, and the Banner Alzheimer's Institute. All corporate rights, data, and intellectual-property assets are wholly owned or held under an exclusive, assignable University of Arizona license with no third-party obligations.

Primary Indication Addressed

Vascular dementia is caused by decreased brain blood flow and increased brain inflammation; resulting in loss of brain health & function and robbing precious memories and time with family and friends.

Vascular dementia is caused by decreased brain blood flow and increased brain inflammation; resulting in loss of brain health & function and robbing precious memories and time with family and friends.

Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.
Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.
Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.
Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.

ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.

Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.

Primary Indication Addressed

Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.
Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.
Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.
Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.

Primary Indication Addressed

Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.
Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.
Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.
Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050.
Cognitive impairment and memory loss caused by decreased brain blood flow, decreased brain oxygenation and brain inflammation are serious problems often resulting from treatments for other medical conditions such as heart disease, major invasive surgery and vascular dementia. In addition, scientific studies have linked early Alzheimer’s to inflammation in the brain. There are currently no effective treatments for inflammation related brain disease and memory loss.
ProNeurogen Therapeutics’ novel peptides inhibit this inflammatory cascade and improve brain blood flow. These peptides are designed to significantly improve serum half-life and penetrate the blood-brain-barrier. These peptides act to inhibit the inflammatory pathways at both the level of brain blood vessels and the brain itself.